Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) rose over 5% following the announcement of an exclusive licensing agreement with Madrigal Pharmaceuticals for the development, production, and commercialization of the oral small molecule GLP-1 receptor agonist SYH2086 [1] Group 1 - CSPC Pharmaceutical Group's stock increased by 5.15%, reaching HKD 10.62, with a trading volume of HKD 608 million [1] - The agreement grants Madrigal exclusive rights to develop, produce, and commercialize SYH2086 globally, while CSPC retains rights to develop and sell other oral small molecule GLP-1 receptor agonists in China [1] - CSPC is entitled to receive up to USD 2.075 billion in total consideration, which includes an upfront payment of USD 120 million, potential milestone payments of up to USD 1.955 billion, and high double-digit sales royalties based on annual net sales of SYH2086 [1]
港股异动 | 石药集团(01093)涨超5% 与Madrigal订立最高20.75亿美元的独家授权协议